Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives
Atherosclerosis represents an important chronic inflammatory process associated with several pathophysiological reactions in the vascular wall. The arachidonic acid, released by phospholipase A2, is an important substrate for the production of a group of lipid mediators known as leukotrienes, which...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2009/737282 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565727992741888 |
|---|---|
| author | Graziano Riccioni Alessandra Zanasi Nicola Vitulano Barbara Mancini Nicolantonio D'Orazio |
| author_facet | Graziano Riccioni Alessandra Zanasi Nicola Vitulano Barbara Mancini Nicolantonio D'Orazio |
| author_sort | Graziano Riccioni |
| collection | DOAJ |
| description | Atherosclerosis represents an important chronic inflammatory process associated with several pathophysiological reactions in the vascular wall. The arachidonic acid, released by phospholipase A2, is an important substrate for the production of a group of lipid mediators known as leukotrienes, which induce proinflammatory signaling through the activation of specific BLT and CysLT receptors. The interaction of these substances in the vascular wall determines important morphological alterations like the early lipid retention and the accumulation of foam cells, the development of intimal hyperplasia, and advanced atherosclerotic lesions, and it plays an important role in the rupture of atherosclerotic plaque. Many studies regarding myocardial ischemia and reperfusion show that leukotriene signaling may be involved in the development of ischemic injury. For these, reasons both leukotriene synthesis inhibitors and leukotriene receptor antagonists have been suggested for inducing beneficial effects at different stages of the atherosclerosis process and may represent a new therapeutic target in the treatment of atherosclerotic vessel diseases, in particular in acute coronary syndrome. |
| format | Article |
| id | doaj-art-8bbbb9367e4d431881b361253bad32cb |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-8bbbb9367e4d431881b361253bad32cb2025-02-03T01:06:52ZengWileyMediators of Inflammation0962-93511466-18612009-01-01200910.1155/2009/737282737282Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy PerspectivesGraziano Riccioni0Alessandra Zanasi1Nicola Vitulano2Barbara Mancini3Nicolantonio D'Orazio4Cardiology Unit, “San Camillo de Lellis” Hospital, Manfredonia, Foggia, ItalyCardiology Unit, University of Foggia, Foggia, ItalyCardiology Unit, Catholic University, Roma, ItalyDepartment of Biomedical Sciences, University of Chieti, ItalyDepartment of Biomedical Sciences, University of Chieti, ItalyAtherosclerosis represents an important chronic inflammatory process associated with several pathophysiological reactions in the vascular wall. The arachidonic acid, released by phospholipase A2, is an important substrate for the production of a group of lipid mediators known as leukotrienes, which induce proinflammatory signaling through the activation of specific BLT and CysLT receptors. The interaction of these substances in the vascular wall determines important morphological alterations like the early lipid retention and the accumulation of foam cells, the development of intimal hyperplasia, and advanced atherosclerotic lesions, and it plays an important role in the rupture of atherosclerotic plaque. Many studies regarding myocardial ischemia and reperfusion show that leukotriene signaling may be involved in the development of ischemic injury. For these, reasons both leukotriene synthesis inhibitors and leukotriene receptor antagonists have been suggested for inducing beneficial effects at different stages of the atherosclerosis process and may represent a new therapeutic target in the treatment of atherosclerotic vessel diseases, in particular in acute coronary syndrome.http://dx.doi.org/10.1155/2009/737282 |
| spellingShingle | Graziano Riccioni Alessandra Zanasi Nicola Vitulano Barbara Mancini Nicolantonio D'Orazio Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives Mediators of Inflammation |
| title | Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives |
| title_full | Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives |
| title_fullStr | Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives |
| title_full_unstemmed | Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives |
| title_short | Leukotrienes in Atherosclerosis: New Target Insights and Future Therapy Perspectives |
| title_sort | leukotrienes in atherosclerosis new target insights and future therapy perspectives |
| url | http://dx.doi.org/10.1155/2009/737282 |
| work_keys_str_mv | AT grazianoriccioni leukotrienesinatherosclerosisnewtargetinsightsandfuturetherapyperspectives AT alessandrazanasi leukotrienesinatherosclerosisnewtargetinsightsandfuturetherapyperspectives AT nicolavitulano leukotrienesinatherosclerosisnewtargetinsightsandfuturetherapyperspectives AT barbaramancini leukotrienesinatherosclerosisnewtargetinsightsandfuturetherapyperspectives AT nicolantoniodorazio leukotrienesinatherosclerosisnewtargetinsightsandfuturetherapyperspectives |